Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2025-12-27 @ 9:31 PM
Study NCT ID:
NCT04478266
Status:
TERMINATED
Last Update Posted:
2025-09-11
First Post:
2020-07-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Sponsor:
Sanofi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10-14
Start Date Type:
ACTUAL
Primary Completion Date:
2022-06-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-05-26
Completion Date Type:
ACTUAL
First Submit Date:
2020-07-10
First Submit QC Date:
None
Study First Post Date:
2020-07-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-06-13
Results First Submit QC Date:
None
Results First Post Date:
2023-07-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-10
Last Update Post Date:
2025-09-11
Last Update Post Date Type:
ESTIMATED